EXPLORATORY STUDY OF TG02-TREATMENT AS MONOTHERAPY OR IN COMBINATION WITH PEMBROLIZUMAB TO ASSESS SAFETY AND IMMUNE ACTIVATION IN PATIENTS WITH LOCALLY RECURRENT ONCOGENIC RAS EXON 2 MUTANT RECTAL CANCER: